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Abstract Childhood neurotransmitter disorders are
increasingly recognised as an expanding group of inherited
neurometabolic syndromes. They are caused by disturbance
in synthesis, metabolism, and homeostasis of the monoamine
neurotransmitters, including the catecholamines (dopamine,
norepinephrine, and epinephrine) and serotonin. Distur-
bances in monoamine neurotransmission will lead to neu-
rological symptoms that often overlap with clinical features
of other childhood neurological disorders (such as hypoxic
ischaemic encephalopathy, cerebral palsy, other movement
disorders, and paroxysmal conditions); consequently, neu-
rotransmitter disorders are frequently misdiagnosed. The
diagnosis of neurotransmitter disorders is made through
detailed clinical assessment, analysis of cerebrospinal fluid
neurotransmitters, and further supportive diagnostic
investigations. Early and accurate diagnosis of neurotrans-
mitter disorders is important, as many are amenable to
therapeutic intervention. The principles of treatment for
monoamine neurotransmitter disorders are mainly directly
derived from understanding these metabolic pathways. In
disorders characterized by enzyme deficiency, we aim to
increase monoamine substrate availability, boost enzyme co-
factor levels, reduce monoamine breakdown, and replace
depleted levels of monoamines with pharmacological ana-
logs as clinically indicated. Most monoamine neurotrans-
mitter disorders lead to reduced levels of central dopamine
and/or serotonin. Complete amelioration of motor symptoms
is achievable in some disorders, such as Segawa’s syndrome,
and, in other conditions, significant improvement in quality
of life can be attained with pharmacotherapy. In this review,
we provide an overview of the clinical features and current
treatment strategies for childhood monoamine neurotrans-
mitter disorders.
Key Points
Monoamine neurotransmitter disorders associated
with abnormal dopamine metabolism are associated
with predominantly neurological phenotypes
Mononeurotransmitter disorders are underrecognised
despite many being treatable and
pharmacoresponsive and should be considered in
those presenting with movement disorder and
unexplained cerebral palsy
Treatment strategies should be tailored to the specific
neurotransmitter defect with input from the expert
neurologist
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1 Background
The monoamine neurotransmitters include the catechola-
mines dopamine, norepinephrine and epinephrine, and
serotonin. These biogenic amines are critically involved in
signaling pathways in the central and peripheral nervous
system. They play a direct role in the regulation of
movement, activity levels, mood, attention, and sleep, as
well as maintenance of vascular tone, blood flow, ther-
moregulation, and modulation of pain mechanisms [1, 2].
Disruption of monoamine neurotransmitter synthesis,
metabolism, and homeostasis leads to diverse neurological
manifestations in childhood and include developmental delay,
motor disorders, epilepsy, autonomic dysfunction, and neu-
ropsychiatric features. More specific clinical features sug-
gestive of dopamine disorders include dystonia, with
fluctuation of symptoms (e.g. diurnal variation), tremor, brisk
deep tendon reflexes, oculogyric crises, palpebral ptosis, axial
hypotonia, hypersalivation, developmental delay, feeding
difficulties, excessive sweating, and temperature instability
[3]. These features overlap with clinical symptoms described
in other neurological syndromes such as hypoxic ischemic
encephalopathy, cerebral palsy, paroxysmal disorders, and the
epileptic encephalopathies, which can make the diagnosis of
neurotransmitter disorders challenging. An understanding of
the biochemical pathways of monoamine neurotransmitter
synthesis, metabolism, and transport is valuable in accurate
diagnosis and also underpins the available therapeutic options
for this spectrum of disorders.
2 Dopamine and Serotonin Biosynthesis: Rationale
for Treatment Strategies
The process of neurotransmission requires (1) synthesis of
the neurotransmitter in the presynaptic nerve terminal, (2)
storage in presynaptic vesicles, (3) regulated release into
the synaptic cleft, (4) action at specific receptors at the
postsynaptic interface, and (5) a means of termination of
action of the released neurotransmitter (either degradation
or reuptake). The monoamine biosynthesis pathway in its
entirety is illustrated in Fig. 1.
The principles of treatment for monoamine neurotrans-
mitter disorders are directly derived from understanding
these metabolic pathways. The sites of common dopami-
nergic-specific pharmacotherapy are summarized in Fig. 2.
In disorders characterized by enzyme deficiency, we aim to
increase monoamine substrate availability, boost enzyme
co-factor levels, reduce monoamine breakdown, and
replace depleted levels of monoamines with pharmacolog-
ical analogs as clinically indicated. The treatments and
doses discussed in this review are collated from the
expertise and experience cited in landmark papers reporting
these disorders. As the majority are rare conditions, robust
evidence for efficacy remains limited, and doses and drug
strategies are more reliant on expert opinion.
Most neurotransmitter disorders lead to reduced levels
of central dopamine and/or serotonin. Treatment of neu-
rotransmitter disorders can therefore include the following
strategies.
2.1 Replacement of Precursors of Dopamine
and Serotonin
Levodopa (L-dopa) and 5-hydroxytryptophan (5-HTP) can
be used to replenish central dopamine and serotonin. L-dopa
therapy has been used for decades in dystonia, with fluctu-
ation and Parkinson’s disease, where dopamine deficiency is
attributed in part to presynaptic dopaminergic neuronal
degeneration [4]. L-dopa is also used to treat several child-
hood-onset monoamine neurotransmitter disorders where
dopamine deficiency results from either impaired dopamine
or pterin synthesis, with the aim of increasing central dopa-
mine levels. Knowledge and understanding of the specific
neurotransmitter disorder being treated is paramount, as L-
dopa is not indicated in all monoamine neurotransmitter
disorders. For example, it is considered inappropriate for the
vast majority of aromatic L-amino acid decarboxylase
(AADC) deficiency patients and not used in dopamine
transporter deficiency syndrome (DTDS). Knowledge of the
specific defect also guides the appropriate dose ranges typ-
ically used, as these also differ from one neurotransmitter
disorder to another (see Table 1 for example, where the L-
dopa dosage range for autosomal dominant guanosine tri-
phosphate [GTP] cyclohydrolase [AD GCH] deficiency is
different to that for treatment of tyrosine hydroxylase [TH]
deficiency). For all dopamine deficiency syndromes, a slow
and steady titration regimen is recommended to assess effi-
cacy and minimize risk of dose-related side effects.
Peripheral AADC inhibitors such as carbidopa or ben-
serazide are frequent concomitant treatments with L-dopa
to prevent peripheral decarboxylation, thereby enabling
more L-dopa to reach the central nervous system. Unlike L-
dopa, carbidopa and benserazide cannot cross the blood–
brain barrier. Within the central nervous system, L-dopa is
further metabolized to dopamine by the enzyme AADC
(Fig. 1). L-dopa administration is associated with a range of
side effects such as nausea, vomiting, dose-related dyski-
nesia, hallucinations, and mood disorders.
5-HTP is used as an adjunct treatment for pterin defects
where there are low central serotonin levels. 5-HTP is the
biosynthetic precursor to serotonin that can be adminis-
tered orally and then crosses the blood–brain barrier to
reach the central nervous system. The aim of 5-HTP
treatment is to increase serotonin precursor levels, with
dosage often being limited by side effects, predominantly
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nausea, vomiting, and diarrhea. The clinical treatment
response is more difficult to assess with 5-HTP than with
L-dopa, but improvement in sleep, motor and cognitive
aspects in the pterin disorder sepiapterin reductase (SPR)
deficiency have been attributed to 5-HTP therapy [5].
2.2 Supplementation of Enzyme Co-Factors
Further strategies to increase central neurotransmitter
availability include co-factor supplementation to boost
enzyme activity and thereby increase bioavailability of
monoamines. There are two key enzyme co-factors in the
monoamine neurotransmitter synthesis pathway, as previ-
ously discussed (Fig. 1), namely tetrahydrobiopterin (BH4)
and pyridoxal phosphate (B6).
Primary synthesis of dopamine and serotonin through TH
and tryptophan hydroxylase is dependent on BH4, and thus
BH4 deficiency leads to reduced levels of both neuro-
transmitters. Three known BH4 deficiency disorders
(autosomal recessive GCH, dihydropteridine reductase
[DHPR], and 6-pyruvoyl-tetrahydropterin synthase [PTPS]
deficiency) are associated with hyperphenylalaninemia and,
Fig. 1 Flow diagram of the monoamine neurotransmitter biosynthe-
sis pathway. The initial substrates for dopamine and serotonin
synthesis are aromatic amino acids tyrosine and tryptophan that enter
the brain via the large neutral amino acid transporter. They are
hydroxylated by tyrosine hydroxylase (TH) and tryptophan hydrox-
ylase (TPH) to levodopa (L-dopa) and 5-hydroxytryptophan (5-HTP),
respectively, and are both subsequently decarboxylated by aromatic L-
amino acid decarboxylase (AADC) to yield the active neurotrans-
mitters dopamine and serotonin. AADC activity is dependent on its
cofactor pyridoxal 5 phosphate. Dopamine and serotonin are further
catabolized by monoamine oxidase (MAO) and catechol-O-methyl
transferase (COMT) to form 3-methyl 4-hydroxyphenylglycol
(MHPG) and homovanillic acid (HVA) from dopamine and 5-hy-
droxyindoleacetic acid (5-HIAA) from serotonin. These are the stable
metabolites measured in the cerebrospinal fluid for neurotransmitter
analysis, and are often the key to diagnosis of a childhood monoamine
neurotransmitter disorder. L-dopa is metabolised by COMT to
3-OMethyldopa (3-OMD) and then Vanillactic acid (VLA). Both
tyrosine hydroxylase and tryptophan hydroxylase activity require the
co-factor tetrahydrobiopterin (BH4). Therefore enzymatic deficien-
cies in the pterin synthesis pathway that affect the levels of this
essential cofactor will lead to reduced levels of the monoamine
neurotransmitters. BH4 is synthesized in four steps from guanosine
triphosphate (GTP) that are dependent on the enzyme activity of
guanine triphosphate cyclohydrolase 1 (GTPCH 1), 6-pyruvoyl-
tetrahydrobiopterin synthase (PTPS), aldose reductase (AR), and
sepiapterin reductase (SPR). The major site of regulation of BH4
biosynthesis is at the level of GTP cyclohydrolase. After coupling as
an active co-factor to the aromatic amino hydroxylases (tyrosine and
tryptophan hydroxylase), BH4 is regenerated through oxidation by
tetrahydrobiopterin-4a-carbinolamine to form quinoid dihydrobiop-
terin (qBH2) and is subsequently converted back to the active co-
factor by dihydrobiopteridine reductase (DHPR). The biogenic
amines are illustrated in blue boxes, with the sites of enzyme or
cofactor deficiency leading to neurotransmitter disorder highlighted in
red boxes with corresponding key for abbreviations used. AD
aldehyde dehydrogenase, DOPAC 3,4-dihydroxyphenylacetic acid,
DBH dopamine b hydroxylase, GTPCH guanosine triphosphate
cyclohydrolase, H2NP2 dihydroneopterin triphosphate, 3-MT 3-meth-
oxytyramine, PCD pterin-4a-carbinolamine dehydratase, PLP pyri-
doxal phosphate, PNMT phenylethanolamine N-methyltransferase,
TH tyrosine hydroxylase, VMA vanillylmandelic acid
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in these, BH4 co-factor supplementation may be utilized
and is more commonly given as combination treatment with
L-dopa. BH4 may help to reduce phenylalanine levels, as
significantly raised phenylalanine is associated with acute
neurological presentation with encephalopathy and longer-
term neurological sequelae. BH4 supplementation has been
used infrequently with pterin defects without hyperphen-
ylalaninemia (sometimes in SPR deficiency and very rarely
in AD GTP cyclohydrolase [GCH] deficiency). Again, the
indication for BH4 supplementation is dependent on
knowledge of the specific pterin defect identified.
B6 is another essential co-factor for reactions catalyzed
by AADC, required for the conversion of 5-HTP and
L-dopa to serotonin and dopamine, respectively, and thus
an essential co-factor supplement in AADC deficiency to
potentiate residual enzyme activity.
2.3 Use of Monoamine Analogs
Dopamine agonists are used to directly stimulate the
postsynaptic dopamine receptors in disorders of dopamine
deficiency (Fig. 2). Agonists are subdivided into D1-like
(D1, D5) and D2 (D2, D3, D4) receptors [6]. Several dopa-
mine agonists are available, including those with an ergo-
line structure (bromocriptine, pergolide, cabergoline) as
well as non-ergoline structured compounds (rotigotine,
pramipexole, ropinirole, aripiprazole). Each has an indi-
vidual dopamine receptor affinity profile, although, to date,
the clinical application of differing properties is unclear.
The dopamine agonists used in movement disorders have
higher binding affinity towards D2 receptors and are
commonly tried as a second-line agent in children who
have either not tolerated or not responded to L-dopa therapy
Fig. 2 Schematic diagram dopaminergic neurotransmission and sites
of common drug treatments and novel neurotransmitter disorders. The
presynaptic neuron is illustrated in blue, with dopamine is represented
as red circles and postsynaptic neuron in green. Following dopamine
synthesis, it is packaged into synaptic secretory vesicles (orange
circles) through VMAT (purple symbol). Presynaptic uptake of
dopamine is-facilitated by dopamine transporter (blue transmembrane
protein symbol) and deficiencies in VMAT and DAT are the most
recent neurotransmitter transport disorders to be described. Sites for
pharmaco-treatment are replacement of L-dopa, and alternative
stimulation of the postsynaptic dopamine receptors (light orange
symbols). MAO-B is represented as a green oval and acts to
metabolize dopamine into HVA. Inhibition of MAO-B is a pharmaco-
target to increase intrinsic dopamine. AADC aromatic amino acid
decarboxylase, B6 pyridoxal phosphate, BH4 tetrahydrobiopterin, D1
postsynaptic dopamine receptor type 1, D2 postsynaptic dopamine
receptor type 2, DAT dopamine transporter, DTDS dopamine transport
deficiency syndrome, MAO monoamine oxidase, MAO-B monoamine
oxidase type B, PITX3 PITX3 gene, TH tyrosine hydroxylase, VMAT2
vesicular monoamine transporter 2
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in our clinical practice. The main side effects of dopamine
agonists are nausea and vomiting, which can be managed
well with concomitant use of domperidone, and clinicians
should be vigilant for the occurrence of excessive sleepi-
ness and emotional lability. In general, if a patient has
failed to gain significant benefit from one dopamine ago-
nist, it is unlikely another will be successful, although it
may be helpful to consider alternative preparations such as
rotigotine patches that allow transdermal controlled drug
release over 24 h if dose-related fluctuations have been
experienced with orally administered agents.
2.4 Use of Agents That Modify Metabolism
of Dopamine/Serotonin
Monoamine oxidase type A (MAO-A) primarily metabo-
lizes norepinephrine and serotonin, whilst MAO type B
(MAO-B) primarily metabolizes dopamine into homova-
nillic acid (HVA) (Fig. 1). MAO-B inhibitors are therefore
used to prevent the metabolism of dopamine at the synaptic
level. Selegiline is commonly used in children (Fig. 2).
MAO-B inhibitors can be used as an alternative/adjunct
therapy in conditions unresponsive to L-dopa or to enable
reduction of L-dopa dose. Selegiline is the L-isomer of N-
propynyl-methamphetamine and an irreversible inhibitor of
MAO-B. It is metabolized to an amphetamine derivative
that can lead to stimulant effects [7]. This may be beneficial
but can have intolerable side effects, including sleep dis-
turbance and hallucinations, as well as dry mouth and
hypotension [7]. At higher doses of more than 10 mg,
selegiline loses its selectivity and can inhibit both MAO-A
and MAO-B enzymes. MAO-A is also involved in the
metabolism of tyramine, which is contained in foods such as
cheese, and thus blockade of MAO-A is associated with
raised tyramine levels and subsequently can lead to hyper-
tensive crisis, especially when L-dopa is also given [7].
Selective serotonin-reuptake inhibitors (SSRIs) are also
used in childhood neurotransmitter disorders associated
with low cerebral serotonin. Their mode of action is to
increase the extracellular level of serotonin by inhibiting its
presynaptic reuptake, thereby boosting endogenous sero-
tonin levels. They are most commonly used in psychiatric
disorders but have been used in neurotransmitter move-
ment disorders. Fluoxetine has been used in AADC defi-
ciency [8] because it exhibits high-affinity binding to the
serotonin transporter, inhibiting reuptake inhibition of
synaptic serotonin and enhancing neurotransmission with
minimal effects on norepinephrine and dopamine uptake,
and has minimal binding to postsynaptic receptors [9].
Other drugs targeting the serotonergic system have been
used with variable response, including zolmitriptan and
buspirone in AADC deficiency [10]. The use of MAO-B
inhibitors (selegiline) in conjunction with SSRIs can lead
to serotonergic crisis with clinical features of dyskinesia,
confusion, and hypertension and is managed with com-
bined withdrawal of both medications.
2.5 The Role of Folate
Cerebral folate deficiency (CFD) is characterized by
decreased levels of cerebrospinal fluid (CSF) 5-methyltet-
rahydrofolate in the presence of normal peripheral serum
folate. This causes a broad clinical spectrum of neurolog-
ical disorders, including epilepsy, learning difficulties, and
motor disorders. Primary CFD is attributed to pathogenic
mutations in FOLR1 [11], but CFD can also be secondary
to another neurological disorder (such as a mitochondrial
cytopathy), drug-induced or idiopathic. CFD is specifically
associated with DHPR and AADC deficiency. Treatment
with folinic acid has been successful in restoring cerebral
folate levels and thus it is important to supplement with
folinic acid to prevent further neurological impairment.
DHPR is thought to play an important role in maintaining
folate in its active form [12]. It is recommended that folate
replacement with oral calcium folinate/folinic acid is
instigated routinely in DHPR deficiency. Furthermore, the
catabolism of excess L-dopa in AADC deficiency by cat-
echol-O-methyltransferase (COMT) to 3-OMD is depen-
dent on the methyl donor S-adenosylmethionine (SAM),
which in turn can deplete 5-methyltetrahydrofolate [13,
14]. There is therefore a risk of CFD in both AADC defi-
ciency and other neurotransmitter disorders requiring
chronic L-dopa supplementation that may also necessitate
supplementation with folinic acid.
In this review, we delineate the clinical features of the
dopamine pathway neurotransmitter disorders, and
describe disorder-specific treatment rationales and strate-
gies, ancillary pharmacotreatments, and novel therapeutic
advances.
3 Disorders of Tetrahydrobiopterin (BH4) Synthesis
BH4 deficiency represents a heterogeneous group of met-
abolic disorders caused by defects in the pterin synthesis or
regenerating pathway (Fig. 1). Disorders of BH4 defi-
ciency may result in hyperphenylalaninemia in some con-
ditions, as well as decreased monoamine levels and folate
levels in the CSF. Autosomal recessive GCH-I, DHPR, and
PTPS deficiencies are classically recognized as BH4 bio-
synthesis disorders leading to hyperphenylalaninemia. In
contrast, AD GCH deficiency, SPR deficiency, and pterin-
4a-carbinolamine dehydratase (PCD) deficiency present
without hyperphenylalaninemia.
BH4 deficiencies are treatable disorders and thus thor-
ough diagnostic investigations are mandatory in all patients
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with (1) clinical symptoms of dopamine/serotonin defi-
ciency, (2) elevated bloodspot phenylalanine levels detec-
ted in newborn screening, and (3) unexplained neurological
presentations and raised phenylalanine detected on plasma
amino acid analysis during neurological investigations
[15]. The diagnostic work-up of suspected BH4 deficien-
cies includes (1) the analysis of pterins (neopterin, biop-
terin, and primapterin) in urine or dried blood spots
(DBSs), (2) the measurement of DHPR activity in the
DBSs, (3) CSF HVA and 5-hydroxyindoleacetic acid (5-
HIAA) (are usually decreased, except in some mild forms
of PTPS), and (4) CSF pterin analysis (characteristic CSF
pterin profiles for each BH4 disorder).
3.1 Autosomal Dominant Guanosine Triphosphate
(GTP) Cyclohydrolase Deficiency
The rate-limiting step of BH4 biosynthesis is the GCH-
catalyzed conversion of GTP to dihydroneopterin triphos-
phate. Both AD and recessive forms of the disease are
recognized. AD GCH deficiency is also commonly known
as Dopa-responsive dystonia (DRD), Segawa disease, and
DYT5a [16], and is the most commonly recognized form of
inherited dystonia in childhood, with an incidence of 0.5
per 100,000 [17] (Table 1). It has a female predominance,
with a reported female-to-male ratio from 2:1 to 6:1 [17]
and a classical clinical presentation of childhood-onset
postural dystonia at modal age 6 years (range 1–11 years)
[16]. The postural dystonia most commonly presents in a
lower limb, most classically with unilateral in-turning of
the foot (pes equinovarus) [16]. The most distinctive fea-
tures of AD GCH deficiency include the marked diurnal
fluctuation (often manifesting as ‘evening equinus’) [18] as
well as the obvious and sustained response to L-dopa,
leading to resolution of motor symptoms in the majority of
cases [18, 19]. Segawa [18] has subsequently further
delineated the spectrum of clinical phenotypes categorized
by age at onset and postulated movement presentation,
relating basal ganglia maturation to pathophysiological
mechanism. Childhood onset at a slightly older age
(8 years) commonly presents with a different phenotype of
action dystonia of the neck and shoulder causing retrocollis
and may also be associated with oculogyric crisis. Onset
after 10 years of age commonly presents with an asym-
metric upper limb postural tremor, whilst adult-onset pre-
sentation includes upper limb tremor with some features of
parkinsonism (such as rigidity) affecting gait [19]. Other
movement phenotypes have been described in adults, such
as writer’s cramp and spasmodic dysphonia [20]. Clini-
cians should be aware of atypical presentations such as
apparent ‘diplegic cerebral palsy’, ‘hereditary spastic par-
aparesis’, and paroxysmal exercise-induced dyskinesia, as
the response to L-dopa can be profoundly life altering, with
multiple reports of restoration of ambulation and full res-
olution of motor symptoms in the literature [21–23].
The diagnosis of GCH deficiency is achieved through a
combination of biochemical, genetic, and therapeutic
approaches. The biochemical hallmark identified on CSF
neurotransmitter analysis reveals low levels of HVA
(± HIAA) and decrease in biopterin and neopterin levels,
with normal plasma phenylalanine levels. CSF findings in
AD GCH deficiency are not always classical and other
biochemical and genetic investigations are often required
to make this diagnosis. As well as its role in the mono-
amine synthesis pathway, BH4 is also a cofactor in the
action of phenylalanine hydroxylase in the liver for phen-
ylalanine clearance. The oral phenylalanine load can
therefore be used to determine a pterin defect in patients
with DRDs, particularly those without hyperphenylalani-
nemia. A 100 mg/kg load of phenylalanine is administered,
and phenylalanine levels are measured at 1, 2, 4, and 6 h. A
raised phenylalanine:tyrosine ratio would suggest a BH4
pathway defect, especially if there was associated decrease
in biopterin concentration [24]. Phenylalanine loads need
to be interpreted with caution, as false-positive and -neg-
ative results are sometimes seen; the test is neither 100 %
sensitive nor specific for pterin defects [25]. Genetic con-
firmation of GCH deficiency is reached through testing for
heterozygous mutations of the GCH1 gene on chromosome
14q22.1-q22.2, of which over 100 mutations have been
identified to date. However, variable penetrance has been
observed [20].
3.1.1 Treatment of Autosomal Dominant (AD) GTP
Cyclohydrolase Deficiency
In AD GCH deficiency, the cardinal clinical feature of
dopa responsiveness is elicited by a therapeutic trial of
L-dopa. A trial of combined L-dopa/carbidopa is initiated at
low dose (0.5–1 mg/kg/day) and gradually titrated to a
standard treatment do L-dopa it is unlikely that the diag-
nosis is AD GCH deficiency [18] (Table 1). L-dopa is
effective in almost all patients without relation to age of
onset or longevity of clinical course [18, 19]. Gradual
titration is recommended, as rapid increment of dose can
lead to aggravation of active dystonia symptoms and
intolerable dyskinesia. These side effects are ameliorated
with dose reduction [18, 26]. We recommend the use of
L-dopa in preparations containing adjunct carbidopa (in
ratios of L-dopa:carbidopa of 4:1–10:1) to limit peripheral
L-dopa side effects, as previously discussed. Response to
L-dopa is sustained, and the motor complications secondary
to tolerance encountered in long-term L-dopa therapy (such
as those seen in Parkinson’s disease) are not observed in
AD GCH deficiency. The natural course of AD GCH
deficiency is an initial progressive dystonia that stabilizes,
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and there is usually no requirement to increment the L-dopa
dosage with age or length of treatment [19]. In contrast to
many other conditions of dopamine deficiency, it has been
observed that there is a decrease in L-dopa dosage
requirement to control symptoms over time, as reported in
20 % of adult patients who developed L-dopa-related dys-
kinesia at long-term follow-up [27].
There have been few reports of other pharmacotherapies
used in AD GCH deficiency. Additional BH4 combined
with L-dopa has been used infrequently and reported to
achieve complete resolution of symptoms, but BH4
monotherapy has not been successful [18]. This is reca-
pitulated in animal models, where it has been shown that
administration of BH4 has failed to stimulate dopamine
synthesis despite brain BH4 levels being elevated seven-
fold [28].
3.2 Autosomal Recessive GTP Cyclohydrolase
Deficiency
Autosomal recessive GCH deficiency is characterized by a
complex neurological syndrome of truncal hypotonia,
dystonia, other movement disorders, autonomic dysfunc-
tion, seizures, and developmental delay [29] (Fig. 1).
Affected neonates are often identified on newborn
screening (raised phenylalanine level). CSF HVA and
5-HIAA, BH4, neopterin, and urine pterins are all
reduced. The diagnosis is made through genetic testing for
homozygous or compound heterozygous mutations in the
GCH1 gene, and enzymatic activity can be assayed in skin
fibroblasts [29]. More recently, reports have suggested a
continuous spectrum between AD and autosomal recessive
GCH deficiency, and the division between dominant and
recessive disease forms appears less distinct than previ-
ously reported. The distinguishing biochemical feature of
hyperphenylalaninemia in recessive disease is no longer a
key feature, with several reports of autosomal recessive
GCH deficiency presenting without hyperphenylalanine-
mia and infantile-onset neurological symptoms [20, 30,
31].
3.2.1 Treatment of Autosomal Recessive GTP
Cyclohydrolase Deficiency
Supplementation of BH4 (titrated dosage 1–10 mg/kg/day)
is used to augment the activity of phenylalanine hydroxy-
lase [33] (Table 1). The use of BH4 monotherapy does not
appear to sufficiently increase the synthesis of monoamine
neurotransmitters, and L-dopa and 5-HTP supplementation
are often also required. In autosomal recessive GCH defi-
ciency, higher doses of L-dopa are required than in AD
GCH, titrated up to 10 mg/kg/day. 5-HTP is also titrated up
to doses of 8 mg/kg/day [33].
3.3 Pyruvoyl-tetrahydropterin Synthase (PTPS)
Deficiency
PTPS is the most common pterin defect associated with
hyperphenylalaninemia [32, 33] (Fig. 1). There is a wide
phenotypic spectrum, ranging from mildly affected cases
(children may be relatively asymptomatic on medication)
to quite severe forms of disease. Neonates with PTPS are
frequently small for gestational age with poor suck,
hypotonia, and microcephaly [34]. The range of movement
disorders observed include hypotonia, hypokinesia, rigid-
ity, chorea, dystonia, and oculogyric crisis and, in the
severe form, can be associated with learning disabilities,
epilepsy, and psychiatric features [25].
In the majority, hyperphenylalaninemia is detected on
neonatal blood spot screening with specific features of
reduced biopterin and raised neopterin concentrations in
urine. In the majority, both CSF HVA and 5-HIAA are
decreased but may also be normal in some patients [34].
PTPS deficiency is caused by mutations in the PTS gene,
and the disease is more frequently observed in Asian
populations. There is good genotype–phenotype correla-
tion, with mild phenotypes associated with mutations pre-
serving high residual enzyme activity reported [35].
3.3.1 Treatment of PTPS Deficiency
Early diagnosis and treatment is possible, with detection
through neonatal hyperphenylalaninemia screening on
blood spots (Table 1). The pharmacological aim is to
replace BH4 (1–12 mg/kg/day). L-dopa/carbidopa (with
L-dopa at 4–18 mg/kg/day) and 5-HTP (3–10 mg/kg/day)
are also given, with administration of these three drugs
initiated at low dose with slow increments to avoid side
effects [36]. Medication is usually divided into three to
four doses per day to avoid off-on phenomena. Other
agents used as adjunctive or alternatives to L-dopa include
selegiline, entacapone, and pramipexole [36, 37].
3.4 Sepiapterin Reductase (SR) Deficiency
SPR deficiency is a rarer autosomal recessive pterin disorder
with normal phenylalanine levels caused by mutations in the
SPR gene (Fig. 1). The triad of upward gaze, paroxysmal
stiffening, and hypotonia tends to occur early in infancy as
one of the earliest symptoms [38]. The core clinical features
are axial hypotonia, motor and language delay, oculogyric
crisis, weakness, and dystonia, with diurnal fluctuation of
symptoms [5]. Parkinsonian features, sleep disturbance, and
behavioral and psychiatric abnormalities are also frequently
associated. Only 8 % have normal cognitive abilities, with
the majority having mild to moderate learning disability [5,
39]. The diagnosis is made by CSF analysis, which shows
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low HVA and HIAA with raised total biopterin, dihydrobi-
opterin (BH2) and sepiapterin levels. Urine pterins and
plasma phenylalanine levels are normal, but the phenylala-
nine load test is frequently positive.
3.4.1 Treatment of SR Deficiency
The enzyme activity of SPR is reduced and therapeutic
approaches involve dopamine and serotonin precursor
supplementation (Table 1). Most patients display a dra-
matic response to L-dopa/carbidopa, with improvement in
motor and sleep symptoms [40]. Most patients seem to
respond to combination therapy of L-dopa and 5-HTP.
Some experience side effects such as dose-related dyski-
nesia; therefore, a very low starting dosage (*0.5–2 mg/
kg/day in three to four doses) with slow increment to the
target dose is recommended. The independent benefits of
5-HTP have been difficult to assess, but modest improve-
ment in sleep, motor, and cognitive aspects have been
reported, with 5-HTP doses ranging from 1 to 6 mg/kg/day.
The majority of patients continue to have mild motor and
cognitive problems. The side effects of vomiting, diarrhea,
and abdominal pain are reported with 5-HTP use in this
condition but are resolved by reduction in dose [5].
4 Disorder of BH4 Regeneration
4.1 Dihydropteridine Reductase (DHPR) Deficiency
DHPR deficiency results in a defect of BH4 regeneration,
and is usually detected on newborn screening (hyper-
phenylalaninemia) and subsequently confirmed on direct
enzyme activity measurement on DBS (Fig. 1). The clini-
cal features are recognized to be more severe than in the
other pterin defects, with disease onset in early infancy or
even earlier in the neonatal period, presenting with feeding
difficulties, bulbar dysfunction, hypersalivation, micro-
cephaly, and developmental delay. Associated movement
disorders include limb hypertonia with truncal hypotonia,
dyskinesia, tremor, dystonia, and choreoathetosis [33].
Learning disability and seizures are observed frequently in
this group. Early recognition and prompt treatment of
DHPR deficiency is vital, as 40 % of DHPR-deficient
neonates are asymptomatic [33]. CSF neurotransmitter
profile shows low concentrations of HVA, HIAA, and
folate, raised BH2, and raised/normal biopterin levels. The
disorder is caused by mutations in the QDPR gene.
4.1.1 Treatment of DHPR Deficiency
The therapeutic aims are to replace CSF dopamine and
serotonin as previously described in other pterin disorders,
with L-dopa/carbidopa (5–13 mg/kg/day of L-dopa) and
5-HTP (3–11 mg/kg/day) [33] (Table 1). The use of
monoamine oxidase inhibitors (MAOIs) and dopamine
agonists, such as selegiline, entacapone, and pramipexole,
has been reported in a recent international survey on
patients with BH4 deficiency [33]. The use of BH4 sup-
plementation remains controversial, as DHPR deficiency
patients accumulate 7,8 BH2, which is considered to be
neurotoxic with additional inhibitory effects on aromatic
amino acid hydroxylases. BH2 has also been reported to
uncouple neuronal nitric oxide synthase (NOS) [41]. In
addition, DHPR is thought to play an important role in
maintaining folate in its active form [40]. The risk of
associated CFD (that may cause further neurological
impairment) has led to the recommendation that replace-
ment with oral calcium folinate/folinic acid is commenced
routinely in DHPR deficiency.
4.2 Pterin 4-a Carbinolamine Dehydratase Deficiency
Pterin 4-a carbinolamine dehydratase is required for the
regeneration of BH4 after phenylalanine hydroxylation,
and the enzyme deficiency leads to a mild form of hyper-
phenylalaninemia associated with raised levels of urinary
7-biopterin. PCD deficiency is caused by mutations in the
PCDB gene; affected patients may present with transient
hypertonia but the majority are asymptomatic with nor-
malization of the phenylalanine with normal diet. The
neurotransmitters are normal, and this condition is con-
sidered benign [32] (Fig. 1).
5 Disorder of Dopamine Synthesis
5.1 Tyrosine Hydroxylase (TH) Deficiency
TH deficiency is an autosomal recessive condition caused
by mutations in the TH gene (Fig. 1). TH catalyses the
conversion of tyrosine to L-dopa, which is the rate-limiting
step in catecholamine biosynthesis. This leads to reduced
CSF HVA with normal HIAA and reduced ratio HVA:-
HIAA (usually \1.0). The clinical phenotypic spectrum is
expanding, with two classical phenotypes recognized: (1)
type A, with progressive extrapyramidal movement disor-
der with hypokinetic rigid syndrome and dystonia (onset in
infancy or childhood), (2) and type B, with complex
encephalopathy (onset in the neonatal period or early
infancy) [42]. The majority of patients are identified with
type A phenotype, and diurnal variation of symptoms is
frequently observed.
Children with type B TH deficiency present within the
first 3 months of life with severe Parkinsonism and hypo-
tonia, with cognitive impairment affecting the majority.
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Focal or generalized dystonia with dystonic crises, oculo-
gyric crises, tremor, ptosis, hypersalivation, and autonomic
disturbance are also associated [42]. Up to 50 % of TH
patients have hyperprolactinemia, which may rarely man-
ifest as galactorrhea [42].
More recently, an intermediate clinical phenotype has
been reported [43]. Additionally, within the type A sub-
group, there are also some children who present later in
childhood with gait instability and walking difficulties [42],
suggesting an expanding phenotypic spectrum of disease.
5.1.1 Treatment of TH Deficiency
The dosing regimen for L-dopa treatment in TH deficiency
needs to be tailored specifically to minimize L-dopa
hypersensitivity, otherwise intolerable side effects of
dyskinesia are observed, even at lower dose ranges [44]
(Table 1). In type B TH deficiency, the initiating dose
commences at \0.5 mg/kg/day (in four to six divided
doses per day) with slow titration (over weeks to months)
to upper dose ranges of 2 mg/kg/day according to
response [42]. In type A disease, slow titration of L-dopa
doses to treatment ranges between 3 and 10 mg/kg/day
are used with reported response [42]. In those who tol-
erate L-dopa well, there is a good or moderate response,
with improvement of motor symptoms and movement
disorder. Cognitive abilities are often impaired but are
stable in the majority [42]. The response to L-dopa can be
variable and often ancillary pharmacological agents are
used to managed dystonia (discussed in ancillary
pharmacotherapies).
5.2 Aromatic L-Amino Acid Decarboxylase (AADC)
Deficiency
The clinical presentation and phenotype of AADC defi-
ciency is extremely variable, with onset ranging from
4 months to adulthood, although the majority of patients
present in childhood. Hypotonia and oculogyric crisis are
cardinal features of AADC deficiency; 50 % of patients
present with other movement disorders, including hypoki-
nesia, chorea, dystonia, and bulbar dysfunction [45]
(Fig. 1). Associated features of monoamine neurotrans-
mitter deficiency, such as sleep disturbance, autonomic
dysfunction (primarily ptosis, excessive sweating, temper-
ature instability, nasal congestion, hypersalivation, and
hypotension), insufficient stress response, and irritability
are also observed with cognitive impairment in the
majority [45, 46]. The characteristic CSF neurotransmitter
profile shows low HVA, 5-HIAA, and 3-methoxy-4-
hydroxyphenylglycol with raised 5-HTP, L-dopa, and
3-ortho-methyldopa. AADC enzyme activity in plasma is
very low or absent and urinary catecholamines are raised
(vanillactic acid, 3-orthomethyldopa) [45]. There are no
specific neuroimaging features, but a spectrum of non-
specific changes are reported, including cerebral atrophy,
white matter abnormalities, and thinning of the corpus
callosum. Just under 100 patients have been identified with
AADC deficiency caused by mutations in the DDC gene,
with a founder mutation identified in Taiwanese Chinese
patients (IVS6?4A[T) and one-third of known patients
being of Southern Chinese origin [47].
5.2.1 Treatment of AADC Deficiency
The pharmacological treatment of AADC usually includes
a combination of dopamine agonists, MAOIs, pyridoxine
and folinic acid [10] (Table 1). L-Dopa is not currently
used in the majority of AADC deficiency patients, as
L-dopa accumulation leads to depletion of SAM that is
potentiated by the AADC deficiency [48]. However, three
siblings with an homozygous point mutation (c.387 G[A)
in exon 3 showed significant response to L-dopa and pyri-
doxal-5-phosphate, with improvement in dystonia but
persistence of behavioral problems. This specific mutation
leads to a distinct decreased affinity between AADC
enzyme and L-dopa, affecting the catalytic site or binding
site for the pyridoxal phosphate (PLP) cofactor and thus
L-dopa is therapeutic [13].
Supplementation with the AADC enzyme cofactor pyr-
idoxine to a maximum dose of 200 mg/day is standard
treatment for AADC deficiency. AADC deficiency is
treated with vitamin B6 in the form of pyridoxine with the
aim of boosting residual AADC activity. Pyridoxine is first
phosphorylated to pyridoxine 50-phosphates by pyridoxine
kinase and subsequently converted to PLP by pyri-
dox(am)ine 50-phosphate oxidase (PNPO) [49]. There does
not appear to be a clinical response to pyridoxine treatment
[46], but biochemical response has been observed with
increased CSF HVA levels (vitamin B6 at 100 mg/kg per
day) [50] and increased plasma serotonin levels (vitamin
B6 at 200 mg/day) [51]. An efficacious dose of pyridoxine
in AADC deficiency has not been established. Often vita-
min B6 dose reduction is necessary due to gastrointestinal
side effects [13, 14]. There is growing in vitro evidence
that an optimal level of PLP is important for AADC
maintenance and stability. Indeed, cell line models show
reduced AADC enzyme levels and activity in PLP-depleted
PC12 cells and, in the presence of PLP and an L-dopa
analog, the AADC was protected from proteolysis [52].
Catabolism of excess L-dopa in this condition is initiated by
COMT that converts L-dopa to 3-OMD. The process is
dependent on the methyl donor SAM, which in turn can
deplete 5-methyltetrahydrofolate [13, 14]. The risk of CFD
in this condition therefore necessitates supplementation
with folinic acid/calcium folinate.
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Adjunct treatments are frequently used in AADC defi-
ciency and include dopamine receptor agonists such as
pergolide, bromocriptine, pramipexole, and ropinirole.
More recently, rotigotine patches have been used with
some success [48]. However, the response to dopamine
agonists is highly variable, with some reported improve-
ments in voluntary movements and absence of response in
others [48, 53].
MAOIs such as selegiline and tranylcypromine are also
used frequently in AADC deficiency. The action of MAO-
A inhibitors is to prevent the breakdown of dopamine and
leads to accumulated dopamine and stimulated receptors
that can have an upstream feedback effect of ultimately
decreasing AADC activity [54]. MAO-B inhibitors act on
increasing AADC messenger RNA (mRNA) and protein
potentiating the neuronal response to dopamine without
increasing dopamine or metabolite concentrations. This
effect was observed to be dose dependent in mouse models
receiving selegiline 1 mg/kg/day, with a selective effect on
MAO-B inhibition and increase in AADC mRNA and
protein, whilst high-dose 10 mg/kg/day selegiline treat-
ment inhibits both MAO-A and -B that leads to overall
AADC inhibition [55]. This effect of high-dose MAOIs and
inhibition of AADC is also observed in high non-selective
MAOI phenelzine [56].
Patients with AADC deficiency experience autonomic
dysfunction due to reduced production of noradrenaline
and adrenaline, and current autonomic interventions in
AADC deficiency are usually targeted to specific symp-
toms such as oxymetazoline for nasal congestion. This is a
sympathomimetic nasal spray that has been successfully
used to reduce nasal congestion in one case [46]. In addi-
tion, serotonin is the precursor of melatonin; consequently,
in AADC deficiency, melatonin is likely to be deficient and
may be contributory to abnormal sleep patterns [10].
Melatonin can be given directly as a treatment and has
been reported to be beneficial for the control of sleep dis-
turbances in at least two cases [46].
Symptoms of dystonia in AADC deficiency have been
treated with adjunct agents that are further discussed in the
ancillary drug treatments section. Overall, the response to
treatment in children with AADC deficiency is variable and
often disappointing, which has resulted in the investigation
of novel therapies such as gene therapy for this condition
[57].
5.3 Pyridoxamine 50-Phosphate Oxidase Deficiency
B6 is an essential cofactor for reactions catalyzed by
AADC. Autosomal recessive pyridoxamine 50phosphate
oxidase (PNPO) deficiency leads to reduction in synthesis
of B6 from pyridoxine and pyridoxamine [49]. This
reduces recycling of B6 from pyridamine phosphate,
which consequently impairs dopamine and serotonin. The
neurotransmitter profile is sometimes (but not always)
similar to that seen in AADC deficiency, with low CSF
HVA and HIAA and high levels of L-dopa, 5-HTP, and
3OMD, with raised CSF glycine, taurine, histidine, and
threonine). If this pattern of CSF neurotransmitters and
amino acids is seen, AADC deficiency should be excluded
by measurement of blood AADC activity and also
exclusion of pyridoxine-dependent epilepsy (due to an-
tiquitin gene mutations) through measurement of urinary
aminoadipic semialdehyde. Diagnosis of PNPO deficiency
is suspected if a low CSF B6 level is detected, and is
confirmed through testing for pathogenic mutations in the
PNPO gene on chromosome 17q21.32 [58]. Children
present with a severe pharmaco-resistant neonatal epi-
leptic encephalopathy, and often there is a history of in
utero seizure onset and prematurity [59]. They respond to
treatment with B6 (but not pyridoxine), which can lead to
seizure reduction.
In suspected cases of PNPO deficiency or intractable
neonatal/early infantile seizures, B6 should be trialed at
30 mg/kg/day in three to four divided doses for 3–5 days.
There is risk of prolonged apnea during a trial of B6, and
close cardiorespiratory monitoring and precautions for
respiratory support should be in place as a safeguard. In
confirmed cases, 30–50 mg/kg/day B6 daily should be used
in the long term.
6 Disorders of Dopamine Synthesis Regulation
The PITX3 gene (Fig. 2) activates the TH promoter and
thus regulates dopamine production [60]. Pitx3 (-/-) mice
have a selective loss of dopaminergic neurons in the sub-
stantia nigra and ventral tegmental area, leading to the
significantly reduced dopamine levels in the nigrostriatal
pathway and in the dorsal striatum. The murine model
manifests anomalous striatum-dependent cognitive
impairment and neurobehavioral activity [61, 62]. Treat-
ment with L-dopa, dopamine, or dopamine receptor ago-
nists in these mice leads to reversal of several of their
sensorimotor impairments. A deletion fragment at chro-
mosome 10q24.32 leading to PITX3 gene deletion was
identified in an adolescent with mild learning difficulties,
psychiatric symptoms, hyperactivity, behavior problems,
and sleep disturbance. He had distinctive facial features,
including high forehead, open mouth, synophrys, short
broad nose, and hypoplastic middle phalanges of fifth fin-
gers. Neuroimaging was normal, but CSF neurotransmitter
analysis shows low CSF HVA and HIAA, absent L-dopa,
and low biopterin. L-dopa treatment was initiated at 1 mg/
kg/day and increased to 2.5 mg/kg/day with improvement
in behavior, attention, and sleep [63].
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7 Disorders of Dopamine Transport
7.1 Brain Dopamine—Serotonin Vesicular Transport
Disease
Brain dopamine–serotonin vesicular transport disease is a
novel neurotransmitter ‘transportopathy’ that has been
recently identified (Fig. 2). It is caused by mutations in the
SLC18A2 that encodes for the vesicular monoamine
transporter 2 (VMAT2) (Fig. 2). This protein is responsible
for dopamine–serotonin loading into the synaptic vesicles
for subsequent monoamine neurotransmission [64]. A loss-
of-function mutation in SLC18A2 was identified in a highly
consanguineous family with eight members affected. The
clinical features at presentation in childhood included
developmental delay and axial hypotonia in infancy, with
an eye movement disorder and oculogyric crises. In ado-
lescence, clinical features of bulbar dysfunction, sleep
disturbance, ptosis, hypomimia, and facial dyskinesia, tre-
mor, ataxia, and parkinsonian shuffling gait were reported.
Neuroimaging studies were normal and CSF neurotrans-
mitter profile (available in one case) was normal. The
urinary neurotransmitters were abnormal, showing raised
levels of HIAA, HVA, and low urinary epinephrine and
dopamine. There was an adverse reaction to L-dopa, with
deterioration in the movement disorder (worsening chorea
and dystonia). However, a trial of the dopamine receptor
agonist pramipexole resulted in complete and sustained
amelioration of the parkinsonism–dystonia motor symp-
toms, leading to restoration of ambulation in some, with
tolerable side effects of hyperactivity and weight loss
observed [65].
7.2 Dopamine Transporter Deficiency Syndrome
Dopamine transporter deficiency is an autosomal recessive
condition caused by pathogenic mutations of SLC6A3 that
encodes for the dopamine transporter [64] (Fig. 2). Loss-
of-function mutations lead to defective presynaptic uptake
of dopamine, with accumulation of synaptic dopamine,
which is catabolized and results in the characteristic raised
HVA levels in CSF. The dopamine transporter does not
affect the serotonin pathway and thus CSF HIAA levels are
normal. The CSF neurotransmitter profile of raised CSF
HVA:HIAA ratio [5 is described in all reported cases of
this disorder [66]. DTDS clinically presents in infancy with
feeding difficulties and irritability with axial hypotonia.
Over time, children develop a progressive dystonic and
dyskinetic movement disorder with eye involvement [66].
This condition is under-recognized and frequently mis-
diagnosed as dyskinetic cerebral palsy. During childhood,
there is evolution of prominent parkinsonian features, with
bradykinesia, hypomimia, rigidity, and resting tremor, with
death in some patients in adolescence [66]. The phenotypic
spectrum of this condition is expanding, with the first
adults with DTDS now recognized, and indeed increasingly
considered as a differential for monogenic causes of
juvenile and early onset parkinsonism [67, 68]. The
majority of patients are unfortunately unresponsive to
nearly all currently available therapeutic agents, including
L-dopa, anticholinergics, benzodiazepines, and deep brain
stimulation. L-dopa and dopamine agonists such as ropin-
irole/pramipexole have been used with limited improve-
ment in motor symptoms in a minority of patients [65].
8 Secondary Neurotransmitter Abnormalities
Abnormal neurotransmitter profiles are recognized in other
neurological conditions and therefore are not an exclusive
feature of disorders of dopamine synthesis or metabolism.
These so-called ‘secondary’ neurotransmitter abnormalities
are increasingly recognized and reported in several
neurological disorders [69] (such as pontocerebellar
hypoplasia, epilepsy, hypoxic-ischemic encephalopathy,
mitochondrial disorders, infection, and primary genetic
syndromes), and may be indicative of secondary dopami-
nergic derangement due to dopaminergic tract degenera-
tion/dysfunction or effects on dopamine metabolism at a
cellular level.
The clinical interpretation of HVA levels and thera-
peutic strategies can be challenging, and results will often
require discussion with both the neurometabolic laboratory
and a neurologist with neurotransmitter expertise [70]. In
patients with low HVA of undetermined or secondary
origin, the role of L-dopa remains unclear. Certainly, in
some patients with obvious symptoms and signs of dopa-
minergic deficiency (such as Parkinsonism, dystonia, ocu-
logyric crises), there may be a role for the slow
introduction and gradual increase of L-dopa to tolerated
doses. A proportion of these patients show improvement in
motor function [71]. The possibility of treating such
patients with L-dopa and 5-HTP for central dopamine and
serotonin deficiency to improve clinical symptoms and
neurological outcome should therefore be considered [70].
The use of neurotransmitter-replacement therapy in
patients with CSF neurotransmitter abnormality in the
absence of classical features of dopaminergic deficiency
remains controversial.
9 Ancillary Pharmacotherapies
The disorders of monoamine neurotransmitter synthesis
most commonly manifest with hyperkinetic symptoms such
as dystonia, tremor, and chorea. Often, such symptoms do
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not fully respond to standard pharmacotreatments aimed at
restoration of the defect in the monoamine pathway. Other
adjunctive treatments are also often required. Dystonia,
especially, can be difficult to manage in a number of dis-
orders [72]. Symptomatic management aims to relieve
abnormal postures, reduce discomfort, and improve func-
tion and range of movement, and thus requires the com-
bined approach of pharmacotherapies with physical
therapy and orthotic management to prevent contractures.
Anticholinergic medications are most beneficial in the
treatment of generalized and segmental dystonia and
overall, trihexyphenydyl is generally well tolerated, start-
ing at a low dose of around 1 mg/day and gradually
incrementing to a maximum of 12 mg/day. It is well rec-
ognized that children tolerate higher dosages than adults,
and often doses are increased much beyond these recom-
mended doses. The mechanism of action is likely to be a
central antimuscarinic effect [73]. It is frequently used in
AADC deficiency and also sometimes in the management
of GCH deficiency, especially for those who have experi-
enced L-dopa-related dyskinesia [17, 26, 74, 75]. The side
effects are dose related and include drowsiness, confusion,
hallucinations, urinary retention, constipation, dry secre-
tions, anorexia, confusion, and psychosis [75]. These are
best avoided through slow titration and can be ameliorated
with dose reduction. Benztropine is another anticholinergic
drug used for dystonia management; it has both anticho-
linergic and antimuscarinic effects, and blocks dopamine
uptake by inhibiting presynaptic uptake. Doses of 1–4 mg/
day are recommended [75].
GABA-ergic agents are also used in the management of
dystonia. Benzodiazepines can also be used in intractable
dystonia and act by binding to the GABA2 receptors-ion
channel complex, thereby increasing chloride entry into the
cell and enhancing GABA-mediated inhibition. The main
side effect is sedation that can be minimized through
careful titration of dose. Oral baclofen is a GABA agonist
that stimulates the metabotropic GABA-B autoreceptor,
but the mechanism of benefit for dystonia is unknown. The
starting dose is 0.25 mg/kg three times a day (tid),
increasing every 3 days to maximum age-related dose
(recommendations 5 mg tid in children aged [10 years).
However, higher doses (with doses being gradually
increased to avoid side effects) are often well tolerated in
older children/adolescents. From personal experience,
many older children tolerate the adult dosing recommen-
dations of 10 mg tid. The main side effects are lethargy,
dry mouth, and dizziness; rapid withdrawal may produce
seizures, and tapered withdrawal is advised.
Clonidine, an a adrenergic agonist, is widely used for
tics in Tourette syndrome and in paroxysmal autonomic
instability with dystonia (PAID) but is now increasingly
used in generalized dystonia. The main side effect is
hypotension; sedation and an in-hospital test dose of
0.1 mg/kg is advised at the start of a treatment trial. The
initial dose is 0.1 mg/kg/day in three divided doses,
increasing gradually to 3 mg/kg/day.
Tetrabenazine is also used in hyperkinetic disorders and
is often a first-/second-line agent for chorea. It is a ben-
zoquinolizine that acts by inhibiting VMAT2 and prevents
repackaging of dopamine and serotonin into vesicles for
neurotransmission; it leads to monoamine neurotransmitter
depletion and in particular dopamine depletion [76]. This
reduces dopaminergic neurotransmission in hyperkinetic
movement disorders; clinicians should be aware of the
main side effects of sedation, Parkinsonism, and low mood.
In AADC deficiency and DTDS, episodes of dystonic
crisis are frequently experienced and require emergency
management to prevent complications such as extreme
pain, severely disrupted sleep pattern, abnormal posture
preventing seating, rhabdomyolysis, myoglobinuria, and
dystonia-triggered diaphragmatic splinting, and respiratory
failure. This often requires hospitalization for aggressive
muscle relaxation and sedation and to ablate status dysto-
nicus, with treatments such as intravenous midazolam
infusion, morphine, and, in some cases, general anesthesia.
Gabapentin has been used for neuropathic pain and adult
movement disorders such as restless leg syndrome. A
recent study reported improvement in dystonia in 49 chil-
dren with associated improvement in transfers, sleep, sit-
ting tolerance, mood, tone, involuntary contractions, and
pain. No unexpected side effects were reported at higher
doses [76]. This is an encouraging novel indication for
gabapentin, but further evaluation is required to assess
dosage requirement and response.
10 Future Treatments
A proportion of dopamine metabolism disorders respond
satisfactorily to monoamine replacement and enhancement
pharmacotreatments, whilst others respond poorly, such as
patients with AADC deficiency and DTDS. Thus, novel
treatments are being developed.
Alternative novel treatment strategies are in the early
stages of in vitro development, and include studies on
pseudoexom-exclusion therapy with antisense morphilino
oligonucleotides. Using this approach, the PTPS enzyme
activity in fibroblast cell lines from three PTPS-deficient
patients with intronic mutations resulting in splicing
defects was restored [77].
In addition the role of COMT inhibitors for the treat-
ment of neurotransmitter disorders may need further
exploration, especially as they have been trialed in Par-
kinson’s disease. Early pharmacological agents were
highly toxic and short acting with poor bioavailability;
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however, there have been several approaches to develop
novel COMT inhibitors that are safe and efficacious as
future therapeutic agents [78].
Furthermore, gene transfer technologies have been
developed to deliver an adeno associated virus (AAV)
encoding hAADC for stable expression of AADC enzyme
in the striatum. This experimental technology has previ-
ously been utilized in clinical trials for adult Parkinson’s
disease. AAV hAADC gene therapy was reported to show
stable expression, with improvement in parkinsonian rating
scores and reduction in dopaminergic therapy dosage and
clinical safety [79]. Such studies have paved the way for
clinical trials in gene therapy for AADC deficiency.
Recently, four children underwent AAV-mediated transfer
of human AADC gene through stereotactic injection
bilaterally to the putamen. This has shown promising
results, with improvement in motor symptoms in all the
patients, clinical safety, and increased dopamine and
serotonin levels following gene transfer [57]. Larger clin-
ical trials will be more informative as to the relative benefit
of gene therapy in this group of patients.
Research into dopamine metabolism and dopaminergic
neurons was previously limited by the availability of
in vivo and in vitro models of dopaminergic neuronal
disease. With the advent of pathogenic dopaminergic
neuronal modeling through induced pluripotent stem cells,
the potential for future research to inform disease mecha-
nisms and develop novel treatments such as enzyme-
replacement therapy and gene therapy appear highly
promising.
11 Conclusion
Childhood neurological disorders of dopamine dysregula-
tion are increasingly recognized as an expanding group of
inherited neurometabolic syndromes. They remain chal-
lenging conditions to diagnose, often mimicking other
neurological syndromes. The principles of treatment are to
replace central monoamine neurotransmitters, prevent
monoamine breakdown, enhance enzyme activity, and
increase dopamine receptor activity. For some disorders,
therapeutic interventions can ablate all symptoms but this
is far from universal in this group of disorders. Patients will
often need adjunct therapy for symptomatic control of
features such as dystonia, sleep disturbance, and gastroin-
testinal symptoms. Treatment is also governed by clinical
response and tolerability of side effects. Treatment strate-
gies are often specific to the neurotransmitter disorder
subtype (Table 1); therefore, knowledge of the biochemical
pathway of monoamine neurotransmitter synthesis metab-
olism underpins accurate diagnosis and appropriate thera-
peutic options in this spectrum of disorders. Future
research will no doubt elucidate novel therapeutic strate-
gies to ameliorate the more pharmaco-resistant disorders of
dopamine metabolism.
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